Small Molecule Inhibitors: A New Era in Cancer Treatment

Dear Colleagues,

This Special Issue, “Small Molecule Inhibitors: A New Era in Cancer Treatment”, highlights the transformative role of targeted small-molecule agents in reshaping modern oncology. The growing knowledge of cancer biology has highlighted the shortcomings of conventional therapies, particularly their lack of specificity and high toxicity, spurring research into more precise approaches. Small-molecule inhibitors have emerged at the forefront of this shift, offering the ability to selectively disrupt critical molecular pathways that drive tumor growth, survival, angiogenesis, and metastasis.

What sets this class of agents apart is not only their direct antitumor effects but also their evolving role in modulating the immune landscape. Recent advances reveal that small-molecule inhibitors can reprogram the tumor microenvironment, enhance antigen presentation, and overcome immune evasion mechanisms, making them powerful partners in combination with immunotherapies. This Special Issue brings together cutting-edge research and expert reviews on how these agents are expanding therapeutic horizons—from bench to bedside.

By showcasing breakthroughs, challenges, and future directions, this Special Issue will provide readers with a comprehensive understanding of how small-molecule inhibitors are setting a stage for a new era of precision oncology and immune-responsive cancer therapies.

Prof. Dr. Natarajan Aravindan
Dr. Kousalya Lavudi
Dr. Suman Asalla
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.